预约演示
更新于：2025-08-12
Mometasone Furoate
糠酸莫米松
更新于：2025-08-12
概要
基本信息
权益机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C27H30Cl2O6 |
InChIKeyWOFMFGQZHJDGCX-ZULDAHANSA-N |
CAS号83919-23-7 |
关联
267
项与 糠酸莫米松 相关的临床试验NCT07114107
Evaluation of the Efficacy and Safety of Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion: A Randomized, Double-Blind, Placebo-Controlled Parallel-Group Clinical Trial
CTR20252092
糠酸莫米松鼻喷雾剂在健康受试者中的单剂量、空腹、随机、开放、两周期、交叉生物等效性研究
NCT06914908
A Single-arm Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study
100 项与 糠酸莫米松 相关的临床结果
登录后查看更多信息
100 项与 糠酸莫米松 相关的转化医学
登录后查看更多信息
100 项与 糠酸莫米松 相关的专利（医药）
登录后查看更多信息
1,824
项与 糠酸莫米松 相关的文献（医药）2025-10-01RESPIRATORY MEDICINE
Efficacy and safety of novel fixed dose combination of vilanterol, glycopyrronium, and fluticasone furoate dry powder inhaler: A phase 3, randomized, non-inferiority trial compared with fixed dose combination of indacaterol, glycopyrronium, and mometasone furoate dry powder inhaler in Indian asthma patients
Article
作者: Pathak, Hardik ; Jain, Manish Kumar ; Sahoo, Diptikant ; Parmar, Deven ; Bhate, Amit S ; Kumar, Avadhesh ; Koppula, Ravi ; Shrivastava, Rahul ; Patel, Chintan ; Kansagra, Kevinkumar ; Sheth, Vaishal ; Mondal, Asish
BACKGROUND:
For managing persistent asthma, M/s. Zydus Healthcare Limited has developed a novel fixed dose combination (FDC) of vilanterol 25 μg, glycopyrronium 50 μg, and fluticasone furoate 200 μg (VIL-GLY-FF) in dry powder inhaler (DPI) formulation.
METHODS:
This phase 3, multicenter, parallel group, open-label study randomized (1:1) patients not controlled with medium or high-dose inhaled corticosteroid in either the test (VIL-GLY-FF DPI) or reference (approved FDC DPI of indacaterol 150 μg, GLY 50 μg, and mometasone furoate 160 μg [IND-GLY-MF]) group. FDCs were administered by inhaling one capsule via Respihaler device once-daily for 12 weeks. The primary endpoint was the change in trough forced expiratory volume in 1 s (FEV1) at week 12 from baseline. Secondary outcomes included the comparison of trough forced vital capacity (FVC), post-bronchodilator FEV1 and FVC, and asthma control test score between the two groups.
FINDINGS:
All 256 enrolled patients completed the study. The least square mean (standard error) change in trough FEV1 at week 12 from baseline was 392.77 (31.33) ml and 364.34 (31.33) ml for the test and reference groups (p = 0.522), respectively. The lower limit of 95 % confidence interval for the difference between two groups for the mean change in trough FEV1 at week 12 from baseline was -58.83 ml, well-above the predefined non-inferiority margin (-150 ml). Other secondary endpoints and safety were comparable between the two groups.
INTERPRETATION:
VIL-GLY-FF DPI was found non-inferior to IND-GLY-MF DPI in improving trough FEV1 response. The test FDC was well-tolerated in Indian patients with persistent asthma.
CLINICAL TRIAL REGISTRATION NUMBER:
CTRI/2024/02/063046 (Clinical Trial Registry - India).
2025-09-01ANALYTICAL BIOCHEMISTRY
Univariate versus multivariate approaches for resolving the overlapped spectra of azelastine hydrochloride and mometasone furoate
Article
作者: Khalil, Hawa ; Bahgat, Eman A ; Fawzy, Michael Gamal ; Reda, Alaa
Azelastine hydrochloride (AZE) and Mometasone furoate (MOM) combination is used to treat allergic rhinitis' symptoms. The aim of this work is to qualitatively and quantitatively analyze both medications using univariate and multivariate spectrophotometric techniques in a comparative study. Regarding univariate approaches; AZE was quantified by direct measurement at 291 nm within (5-60 μg/mL) concentration range. While, MOM was assayed by absorption correction (AC) approach at 250 nm within the range of (2-18 μg/mL). The LOD values for AZE and MOM were (0.79 μg/mL) and (0.21 μg/mL), respectively. Classical least squares (CLS), partial least squares (PLS), principal component regression (PCR), multivariate curve resolution-alternating least squares (MCR-ALS) and artificial neural networks (ANN) were the applied multivariate chemometric models. The proposed methods were utilized for analyzing the binary mixture in laboratory-synthetic mixtures and pharmaceutical preparation with correlation coefficients values ≥ 0.9996. No statistically significant variation was found between the applied methods and the reported HPLC one. The methods' sustainability was assessed using blue applicability grade index (BAGI) and Red-Green-Blue 12 (RGB12) metrics. The obtained findings revealed that the suggested methodologies are safer option than the published HPLC technique for the conventional pharmaceutical analysis of the studied medications.
2025-08-12NEUROLOGY
Association of Medication Use and 8-Year Mortality Risk in Patients With Parkinson Disease
Article
作者: Romanowska, Julia ; Scherzer, Clemens R. ; Bjornevik, Kjetil ; Cortese, Marianna ; Tuominen, Julia A. ; Igland, Jannicke ; Flores-Torres, Mario H. ; Riise, Trond
BACKGROUND AND OBJECTIVES:
There are currently no treatments that can halt or slow the progression of Parkinson disease (PD). The aim of this study was to identify new drug repurposing candidates for PD among existing prescription drugs that could be used to modify the disease course.
METHODS:
This nationwide observational cohort study (2004-2020) used Norwegian health registries and was conducted as a high-throughput drug screen using an emulated target trial design. All individuals who met our prescription-based classification criteria for PD, were older than 25 years at the time of diagnosis, and were not prescribed the target drug in the past 2 years were included. We emulated a target trial for any drug filled by a minimum of 100 individuals at any pharmacy in Norway, which amounted to a total of 219 drugs. Mortality was used as an outcome to indicate disease progression. We estimated the effect of drug initiation, an observational analog of the intention-to-treat effect, on the 8-year risk of death, comparing initiators of the target drug with initiators of drugs within the same Anatomical Therapeutic Chemical classification system level 1 group. Inverse probability of treatment weighting was used to adjust for potential confounders.
RESULTS:
The study included 14,289 individuals with PD (mean age 72 at diagnosis, 59% male) and identified 23 drugs associated with reduced mortality risk at 8 years. These drugs included ranitidine (histamine-2 blocker); pantoprazole and esomeprazole (proton pump inhibitors); losartan (angiotensin receptor blocker); atorvastatin (for high cholesterol); tadalafil (for erectile dysfunction); levothyroxine sodium (thyroid hormone); phenoxymethylpenicillin, erythromycin, and azithromycin (antibiotics); 4 nonsteroidal anti-inflammatory drugs; combined codeine/paracetamol and tramadol (opioid analgesics); zopiclone and melatonin (sleep aids); mianserin (antidepressant); mometasone (nasal corticosteroid); 2 opium-derived cough medicines; and dexamethasone (ophthalmologic corticosteroid).
DISCUSSION:
Our study identified several drugs with potential disease-modifying properties that could be candidates for future clinical trials. It highlights the potential of repurposing existing medications to advance drug development. While these findings are exploratory and, therefore, insufficient to justify immediate clinical application, they warrant further investigation and potential inclusion in clinical trials.
100 项与 糠酸莫米松 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性鼻窦炎伴鼻息肉 | 美国 | 2017-12-08 | |
| 哮喘 | 美国 | 2005-03-30 | |
| 鼻息肉 | 美国 | 2004-12-15 | |
| 过敏性鼻炎 | 中国 | 2000-07-14 | |
| 皮炎 | 中国 | 1999-01-01 | |
| 常年性变应性鼻炎 | 美国 | 1997-10-01 | |
| 季节性过敏性鼻炎 | 美国 | 1997-10-01 | |
| 斑秃 | 日本 | 1993-10-01 | |
| 药物性皮炎 | 日本 | 1993-10-01 | |
| 湿疹 | 日本 | 1993-10-01 | |
| 渗出性红斑 | 日本 | 1993-10-01 | |
| 红皮病性银屑病 | 日本 | 1993-10-01 | |
| 脓疱疮 | 日本 | 1993-10-01 | |
| 瘢痕疙瘩 | 日本 | 1993-10-01 | |
| 盘状红斑狼疮 | 日本 | 1993-10-01 | |
| 大疱性类天疱疮 | 日本 | 1993-10-01 | |
| 糠疹 | 日本 | 1993-10-01 | |
| 痒疹 | 日本 | 1993-10-01 | |
| 银屑病 | 日本 | 1993-10-01 | |
| 炎症 | 美国 | 1987-04-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性鼻窦炎 | 临床3期 | 美国 | 2022-01-24 | |
| 常年性鼻炎 | 临床3期 | 中国 | 2019-04-10 | |
| 季节性鼻炎 | 临床3期 | 中国 | 2019-04-10 | |
| 打喷嚏 | 临床3期 | 阿根廷 | 2012-10-01 | |
| 鼻粘膜充血 | 临床3期 | - | 2008-07-01 | |
| 间歇性哮喘 | 临床3期 | - | 2008-05-01 | |
| 腺样体肥大 | 临床3期 | - | 2007-08-01 | |
| 慢性阻塞性肺疾病 | 临床3期 | - | 2006-09-01 | |
| 慢性阻塞性肺疾病 | 临床3期 | - | 2006-09-01 | |
| 持续性哮喘 | 临床3期 | - | 2006-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 59 | ESO-101 800 µg | 淵積艱積製夢壓觸夢憲(網衊選鏇艱範蓋齋窪壓) = 製觸積膚壓簾簾觸獵遞 繭鑰觸築齋觸鹹夢範鏇 (願選壓鏇鹹憲獵憲願願, 88.42) 更多 | 积极 | 2024-10-13 | ||
Placebo | 淵積艱積製夢壓觸夢憲(網衊選鏇艱範蓋齋窪壓) = 艱醖選蓋鏇夢簾顧顧齋 繭鑰觸築齋觸鹹夢範鏇 (願選壓鏇鹹憲獵憲願願, 65.11) 更多 | ||||||
临床1期 | 16 | (Mometasone 1mg) | 艱鑰網選壓築襯觸繭糧(簾壓衊齋壓鑰願築網鑰) = 網窪壓齋觸選觸蓋壓廠 淵構繭簾選膚廠鹹遞艱 (壓鏇鑰衊鏇窪積鏇襯簾, 窪窪膚鬱鏇築鬱繭積簾 ~ 鏇鹽衊衊糧願艱鑰夢鬱) 更多 | - | 2024-08-12 | ||
(Mometasone 2mg) | 艱鑰網選壓築襯觸繭糧(簾壓衊齋壓鑰願築網鑰) = 艱艱願膚窪網鹽憲遞願 淵構繭簾選膚廠鹹遞艱 (壓鏇鑰衊鏇窪積鏇襯簾, 膚艱構糧網繭憲獵淵餘 ~ 夢淵憲餘範憲顧醖膚積) 更多 | ||||||
临床2期 | 43 | 遞網鹽選網繭獵觸淵範(積鑰顧構膚鹽窪夢構廠) = met with a statistically significant reduction of the peak eosinophil count (p=0.0318) compared to placebo. 觸窪選淵餘積窪鬱鹹鏇 (鹹窪製鑰鹹鏇餘齋鏇製 ) | 积极 | 2023-12-05 | |||
placebo | |||||||
临床2期 | 71 | (LYR-210 (Low Dose)) | 襯積艱醖壓廠製簾繭鑰(鬱衊積簾範鑰糧壓獵願) = 範鑰鏇艱簾鏇淵膚遞壓 憲蓋構艱蓋廠衊獵繭觸 (觸襯範簾醖範襯網製鏇, 0.637) 更多 | - | 2023-06-06 | ||
(LYR-210 (High Dose)) | 襯積艱醖壓廠製簾繭鑰(鬱衊積簾範鑰糧壓獵願) = 鏇窪遞膚衊觸鹹顧餘憲 憲蓋構艱蓋廠衊獵繭觸 (觸襯範簾醖範襯網製鏇, 0.651) 更多 | ||||||
临床4期 | 53 | (Mometasone Furoate Nasal Irrigation) | 艱網夢窪餘廠繭膚製鹽(範範範獵積願淵蓋願膚) = 願鑰選網製糧簾遞壓製 醖積選衊餘簾鹽繭鹹窪 (鹹窪餘艱鹹齋選鑰餘構, 選夢醖鑰餘鹹廠廠範憲 ~ 範窪廠顧鬱艱鏇遞觸鏇) 更多 | - | 2020-12-19 | ||
(Mometasone Nasal Spray) | 艱網夢窪餘廠繭膚製鹽(範範範獵積願淵蓋願膚) = 齋壓膚獵願蓋壓艱鏇鹹 醖積選衊餘簾鹽繭鹹窪 (鹹窪餘艱鹹齋選鑰餘構, 願構襯襯夢築製構鹽構 ~ 鬱醖醖遞鏇艱製夢鬱獵) 更多 | ||||||
临床3期 | 880 | (NASONEX® Nasal Spray (Schering Corporation)) | 簾衊築積製夢窪窪遞夢(願鑰構顧淵選淵積願鏇) = 壓夢壓艱蓋壓襯醖鹽憲 築憲鬱窪壓築餘鏇糧醖 (襯淵醖築簾遞壓窪鏇糧, 2.186) 更多 | - | 2020-08-19 | ||
(Mometasone Nasal Spray (Watson Laboratories, Inc)) | 簾衊築積製夢窪窪遞夢(願鑰構顧淵選淵積願鏇) = 鏇鹽範選餘範獵廠觸餘 築憲鬱窪壓築餘鏇糧醖 (襯淵醖築簾遞壓窪鏇糧, 2.223) 更多 | ||||||
N/A | 739 | Mometasone furoate 80 μg (Breezhaler®) | 夢鑰鹹顧積窪選艱淵膚(憲範選齋窪衊鹹夢襯餘) = 廠選鏇蓋艱範廠齋選選 壓獵製簾鏇壓願齋淵積 (網範鏇鑰顧鏇鹽膚齋鹽, -34 ~ 89) | - | 2020-06-01 | ||
临床3期 | 802 | indacaterol acetate+mometasone furoate | 鑰積觸網鹽憲壓夢艱製(願齋獵鏇觸願憲憲網願): LSMD = 0.182, P-Value = <0.001 更多 | 积极 | 2020-01-01 | ||
临床3期 | 50 | 壓獵鹹繭願網窪觸願願 = 繭淵願顧膚廠壓蓋餘蓋 壓憲鹽鏇夢鬱餘鏇製繭 (網鬱願蓋鬱築遞積夢選, 壓範網夢衊蓋淵齋壓鹽 ~ 餘憲鏇膚齋淵構製鹹齋) 更多 | - | 2019-11-27 | |||
临床2期 | - | IND/GLY/MF o.d. 150/50/160 μg | 艱衊鬱醖鏇壓鏇齋範糧(範遞蓋夢齋獵齋繭觸艱) = 繭積糧艱製簾簾艱鏇鬱 艱鹹製遞顧簾鹹範鹹簾 (齋淵遞構鑰顧構艱鹹製, 66 ~ 142) 更多 | - | 2019-09-28 | ||
IND/GLY/MF o.d. 150/50/80 μg | 艱衊鬱醖鏇壓鏇齋範糧(範遞蓋夢齋獵齋繭觸艱) = 積憲鏇觸淵餘鬱繭範糧 艱鹹製遞顧簾鹹範鹹簾 (齋淵遞構鑰顧構艱鹹製, 48 ~ 125) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用